Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid

Oncology Reports

Volumn 12, Issue 5, 2004, Pages 1109-1114

  Vogt, Ulf ^a   Bielawski, Krzysztof P ^b   Bosse, Ulrich ^c   Schlotter, Claus M ^d  

^a European Laboratory Association   (Germany)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c Institute of Pathology   (Poland)

^d KLINIKUM IBBENBÜREN   (Germany)

Author keywords

Anticancer drugs; Atp cva assay; Bisphosphonates; Breast cancer tumour cells; Ex vivo chemosensitivity testing; Ibandronate; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IBANDRONIC ACID; IMIDAZOLE DERIVATIVE; METHOTREXATE; PACLITAXEL; TAXOID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; CARCINOMA; CELL DIVISION; COLLOID CARCINOMA; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CYCLOPHOSPHAMIDE; DIPHOSPHONATES; DRUG SYNERGISM; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMIDAZOLES; METHOTREXATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; PACLITAXEL; TAXOIDS;

EID: 16544379650     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.5.1109     Document Type: Article

References (27)

1. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999. (Pubitemid 29094960)
2. Wilson MA and Calhoun FW: The distribution of skeletal metastases in breast and pulmonary cancer: concise communication. J Nucl Med 22: 594-597, 1981. (Pubitemid 11067854)
3. Hortobagyi GN: Bone metastases in breast cancer patients. Semin Oncol 18(Suppl5): 11-15, 1991.
4. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E and Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558-567, 2001. (Pubitemid 32112871)
5. Mundy GR: Bisphosphonates as anticancer drugs. Exp Opin Invest Drugs 8: 2009-2015, 1999.
6. Coleman RE: Bisphosphonates for the prevention of bone metastases. Semin Oncol 6: 43-49, 2002.
7. Clezardin P: The antitumor potential of bisphosphonates. Semin Oncol 6: 33-42, 2002.
8. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas J A and Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468, 2002.
9. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001. (Pubitemid 32448513)
10. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL and Ambros Y: Zoledronic Acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377-387, 2001. (Pubitemid 33759002)
11. Jagdev SP, Croucher PI and Coleman RE: Zoledronic acid induces apoptosis of breast cancer cells in vitro - evidence for additive and synergistic effects with taxol and tamoxifen. Proc Am Soc Clin Oncol 19: 664a, 2000.
12. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P and Venuta S: Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14: 841-844, 2000. (Pubitemid 30235061)
13. Hiraga T, Hata K and Nishimara R: Combined treatment with bisphosphonates and oral UFT inhibits bone and soft organ metastases and prolongs survival. J Bone Miner Res 14 (Suppl 1): 188, 1999.
14. Köchli OR, Sevin BU, Averette HE and Haller U: Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer. Contrib Gynecol Obstet 19: 12-23, 1994.
15. Köchli OR, Sevin B-U and Haller U: Chemosensitivity testing in gynecologic malignancies and breast cancer. Contrib Gynecol Obstet 19: 108-121, 1994.
16. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso A, Ricks SH, Untch M, Sartori C, and Bruckner HW: Chemosensitivity testing of human tumors using microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma Cancer Res 55: 5276-5282, 1995.
17. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Mueller K, Ackermann T, Glister TJ, Wilhelm LM, Engel H, Mallmann PK and Aandreotti PE: Use of an ex vivo ATP luminescence assay to direct chemotherapy for reccurent ovarian cancer. Anticancer Drugs 9: 51-57, 1998. (Pubitemid 28088179)
18. Vogt U, Striehn E, Bosse U, Klinke F and Falkiewicz B: Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay. Acta Biochim Pol 46: 299-302 1999. (Pubitemid 129632508)
19. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H and Untch M: Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77: 2258-2263, 2000.
20. Neale MH, Lamont A, Hindley A, Kurbacher CM and Cree IA: The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian cancer. Anticancer Drugs 11: 865-871, 2000.
21. De Vita VT Jr: Principles of cancer management: chemotherapy. In: Cancer: Principles and Practice of Oncology. DeVita VT Jr, Heimann S, Rosenberg S (eds). Lippincott-Raven Publishers, Philadelphia, PA, pp333-347, 1997.
22. Cree IA and Kurbacher CM: Individualizing chemotherapy for solid tumors - is there any alternative? Anticancer Drugs 8: 541-548, 1997. (Pubitemid 27373433)
23. Falkiewicz B, Schlotter CM, Bosse U, Bielawski K and Vogt U: c-Myc oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer. Acta Biochim Pol 47: 149-156, 2000.
24. Vogt U, Falkiewicz B, Bielawski K, Bosse U and Schlotter CM: Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay. Acta Biochim Pol 47: 157-164, 2000.
25. Köchli OR, Sevin BU, Perras JP, Angioli R, Steren A, Rodriguez M, Ganjei P and Averette HE: Growth characteristics of nonmalignant cells in the ATP-cell viability assay. Oncology 51: 35-41,1994. (Pubitemid 24008638)
26. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000. (Pubitemid 30175914)
27. Fromigue O, Lagneaux L and Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221, 2000.